Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.

Engström K, Willén H, Kåbjörn-Gustafsson C, Andersson C, Olsson M, Göransson M, Järnum S, Olofsson A, Warnhammar E, Aman P.

Am J Pathol. 2006 May;168(5):1642-53.

2.

Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.

Andersson MK, Göransson M, Olofsson A, Andersson C, Aman P.

BMC Cancer. 2010 Jun 1;10:249. doi: 10.1186/1471-2407-10-249.

3.

The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.

Göransson M, Andersson MK, Forni C, Ståhlberg A, Andersson C, Olofsson A, Mantovani R, Aman P.

Oncogene. 2009 Jan 15;28(2):270-8. doi: 10.1038/onc.2008.378. Epub 2008 Oct 13.

PMID:
18850010
4.

Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.

Göransson M, Elias E, Ståhlberg A, Olofsson A, Andersson C, Aman P.

Int J Cancer. 2005 Jul 1;115(4):556-60.

5.

Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas.

Olofsson A, Willén H, Göransson M, Engström K, Meis-Kindblom JM, Stenman G, Kindblom LG, Aman P.

Int J Oncol. 2004 Nov;25(5):1349-55.

PMID:
15492825
6.

DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.

Bento C, Andersson MK, Aman P.

BMC Cell Biol. 2009 Dec 17;10:89. doi: 10.1186/1471-2121-10-89.

7.

Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.

Åman P, Dolatabadi S, Svec D, Jonasson E, Safavi S, Andersson D, Grundevik P, Thomsen C, Ståhlberg A.

J Pathol. 2016 Apr;238(5):689-99. doi: 10.1002/path.4700.

PMID:
26865464
8.

DDIT3 Expression in Liposarcoma Development.

Kåbjörn Gustafsson C, Engström K, Aman P.

Sarcoma. 2014;2014:954671. doi: 10.1155/2014/954671. Epub 2014 Mar 25.

10.

Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation.

Rodriguez R, Tornin J, Suarez C, Astudillo A, Rubio R, Yauk C, Williams A, Rosu-Myles M, Funes JM, Boshoff C, Menendez P.

Stem Cells. 2013 Oct;31(10):2061-72. doi: 10.1002/stem.1472.

11.

Paratesticular myxoid/round cell liposarcoma harboring type 3 DDIT3-FUS fusion gene: report of a very rare case.

Zozumi M, Nakai M, Matsuda I, Hao H, Tsukamoto Y, Shiraishi Y, Nojima M, Yamamoto S, Hirota S.

Pathol Res Pract. 2013 Feb 15;209(2):124-7. doi: 10.1016/j.prp.2012.10.015. Epub 2012 Dec 28.

PMID:
23276404
12.

Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma.

Riggi N, Cironi L, Provero P, Suvà ML, Stehle JC, Baumer K, Guillou L, Stamenkovic I.

Cancer Res. 2006 Jul 15;66(14):7016-23.

13.

FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells.

Rodriguez R, Rubio R, Gutierrez-Aranda I, Melen GJ, Elosua C, García-Castro J, Menendez P.

Stem Cells. 2011 Feb;29(2):179-92. doi: 10.1002/stem.571.

14.

A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression.

Oikawa K, Tanaka M, Itoh S, Takanashi M, Ozaki T, Muragaki Y, Kuroda M.

Br J Cancer. 2012 Jun 5;106(12):1976-9. doi: 10.1038/bjc.2012.199. Epub 2012 May 15.

15.

The myxoid liposarcoma specific TLS-CHOP fusion protein localizes to nuclear structures distinct from PML nuclear bodies.

Thelin-Järnum S, Göransson M, Burguete AS, Olofsson A, Aman P.

Int J Cancer. 2002 Feb 1;97(4):446-50.

16.

Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development.

Pérez-Mancera PA, Vicente-Dueñas C, González-Herrero I, Sánchez-Martín M, Flores-Corral T, Sánchez-García I.

Carcinogenesis. 2007 Oct;28(10):2069-73. Epub 2007 Apr 29.

PMID:
17468515
17.

Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma.

Ståhlberg A, Kåbjörn Gustafsson C, Engtröm K, Thomsen C, Dolatabadi S, Jonasson E, Li CY, Ruff D, Chen SM, Åman P.

PLoS One. 2014 Nov 13;9(11):e113110. doi: 10.1371/journal.pone.0113110. eCollection 2014.

18.

Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.

Suzuki K, Matsui Y, Higashimoto M, Kawaguchi Y, Seki S, Motomura H, Hori T, Yahara Y, Kanamori M, Kimura T.

PLoS One. 2012;7(5):e36682. doi: 10.1371/journal.pone.0036682. Epub 2012 May 3.

19.

HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.

Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stenman G, Schneider-Stock R, Ståhlberg A, Åman P.

Oncotarget. 2016 Jan 5;7(1):433-45. doi: 10.18632/oncotarget.6336.

20.

Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion.

Bode-Lesniewska B, Frigerio S, Exner U, Abdou MT, Moch H, Zimmermann DR.

Genes Chromosomes Cancer. 2007 Nov;46(11):961-71.

PMID:
17647282

Supplemental Content

Support Center